

Certificate of Analysis

DYRK1B, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-944, 14-944-K, 14-944M

Parent Lot # D14BP004N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal GST-tagged, recombinant, human DYRK1B full length, expressed by baculovirus in Sf21 insect cells. Purified using glutathione agarose followed by gel filtration.

Purity 90% by SDS-PAGE and Coomassie blue staining. MW = 96kDa.

Specific Activity (Parent lot# D14BP004N): 2695U/mg, where one unit of DYRK1B, active activity is defined as 1nmol phosphate incorporated into 50 μ M (RRRFRPASPLRGPPK) per minute at 30°C with a final ATP concentration of 100 μ M.

Formulation: 0.523mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 20mM β -glycerophosphate, 10mM NaF, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 0.4–8.7ng of this lot of enzyme phosphorylated 50 μ M (RRRFRPASPLRGPPK) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as DYRK1B with the translated sequence listed on page three



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3 μ g of DYRK1B, active

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
- (RRRFRPASPLRGPPK):** Use at a final assay concentration of 50 μ M. Prepare a 2.5mM stock and add 0.5 μ l of stock per assay point.
- BSA:** Use at a final assay concentration of 0.5%(w/v). Prepare a 10%(w/v) solution in water and use 1.25 μ l per well.
- DYRK1B, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 0.4–8.7ng per assay point.
- [γ -³³P]ATP:** 2.5 x MgAc/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required).

Assay Procedure (96 well plate format):

- Add 5 μ l of 5 x reaction buffer per assay to wells.
- Add 1.25 μ l 10% BSA to wells
- Add 0.5 μ l of (RRRFRPASPLRGPPK).
- Add **2.5 μ l (0.4–8.7ng) DYRK1B, active.**
- Add 5.75 μ l of dH₂O.
- Add 10 μ l of diluted [γ -³³P]ATP mixture.
- Incubate for 10 minutes at 30°C.
- Stop the reaction by adding 5 μ l of 3% phosphoric acid.
- Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat.**
- Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
- Wash the filtermat once for 2 minutes with methanol.
- Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
- Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

DYRK1B Sequence Information

Protein	human DYRK1B
Tags	N-terminal GST
Native sequence	M230 of the recombinant protein is equivalent to M1 of human DYRK1B
Accession number	GenBank NM_004714

Recombinant DYRK1B amino acid sequence:

```

1  MSPILGYWKI  KGLVQPTRL  LEYLEEKYEE  HLYERDEGDK  WRNKKFELGL  EFPNLPYYID
61  GDVKLTQSMA  IIRYIADKHN  MLGGCPKERA  EISMLEGAVL  DIRYGVSRIA  YSKDFETLKV
121 DFLSKLPEML  KMFEDRLCHK  TYLNGDHVTH  PDFMLYDALD  VVLYMDPMCL  DAFPKLVCFK
181 KRIEAIQID  KYLKSSKYIA  WPLQGWQATF  GGDHPPKSD  LVPRGSKEFM  AVPPGHGPF
241 GFPGQEHTQ  VLPDVRLPR  RLPLAFRDAT  SAPLRKLSVD  LIKTYKHINE  VYYAKKRRRA
301 QQAPPQDSSN  KKEKKVLNHG  YDDDNHDYIV  RSGERWLERY  EIDSLIGKGS  FGQVVKAYDH
361 QTQELVAIKI  IKNKKAFLNQ  AQIELRLELE  MNQHDTEMKY  YIVHLKRHF  FRNHLCLVFE
421 LLSYNLYDLL  RNTHFRGVSL  NLTRKLAQQL  CTALLFLATP  ELSIIHCDLK  PENILLCNPK
481 RSAIKIVDFG  SSCQLGQRIY  QYIQSRFYRS  PEVLLGTPYD  LAIDMWSLGC  ILVEMHTGEP
541 LFSGSNEVDQ  MNRIVEVLGI  PPAAMLDOAP  KARKYFERLP  GGGWTLRRTK  ELRKDYQGGP
601 TRRLQEV LGV  QTGGPGGRR  A  GEPGHSPADY  LRFQDLVLRM  LEYEPAA  RIS  PLGALQHGF
661 RRTADEATNT  GPAGSSASTS  PAPLDTCPSS  STASSISSSG  GSSGSSSDNR  TYRYSNRYCG
721 GPGPPITDCE  MNSPOVPPSQ  PLRPWAGGDV  PHKTHQAPAS  ASSLPGTGAQ  LPPQPRYLGR
781 PPSPTSPPPP  ELMDVSLVGG  PADCSPPHPA  PAPQHPAASA  LRTRMTGGRP  PLPPDDPAT
841 LGPHLGLRGV  PQSTAASS
  
```

Recombinant DYRK1B nucleotide sequence:

```

1  atgtccccta  tactaggtta  ttggaaaatt  aaggcccttg  tgcaaccac  tcgacttctt
61  ttggaatata  ttgaagaaaa  atatgaagag  catttgatg  agcgcatga  aggtgataaa
121  tggcgaaaca  aaaagtttga  attgggtttg  gagtttcca  atcttcctta  ttatattgat
181  ggtgatgtta  aattaacaca  gtctatggcc  atcatacgtt  atatagctga  caagcacaac
241  atgttgggtg  gttgtccaaa  agagcgtgca  gagattcaa  tgcttgaagg  agcggttttg
301  gatattagat  acggtgtttc  gagaattgca  tatagtaaag  actttgaaac  tctcaaagtt
361  gattttctta  gcaagctacc  tgaatgctg  aaaatgttcg  aagatcgttt  atgtcataaa
421  acatatttaa  atggtgatca  tgtaacccat  cctgacttca  tgttgatga  cgctcttgat
481  gttgttttat  acatggacct  aatgtgcctg  gatgcgttcc  caaaattagt  ttgttttaaa
541  aaacgtattg  aagctatccc  acaaattgat  aagtacttga  aatccagcaa  gtatatagca
601  tggcctttgc  agggctggca  agccacgttt  ggtggtggcg  accatcctcc  aaaatcggat
661  ctggttccgc  gtggatccaa  ggaattcatg  gccgtccac  cgggcatgg  tcccttctct
721  ggcttcccag  ggccccagga  gcacacgcag  gtattgctg  atgtgcggct  actgcctcgg
781  aggctgcccc  tggccttcg  ggatgcaacc  tcagccccgc  tgcgtaagct  ctctgtggac
841  ctcatcaaga  cctacaagca  catcaatgag  gtatactatg  cgaagaagaa  gcggcgggac
901  cagcaggcgc  caccagga  ttcgagcaac  aagaaggaga  agaaggctct  gaaccatggt
961  tatgatgacg  acaacatga  ctacatcgtg  cgagtggtgg  agcgtggtgg  ggagcgtctc
1021  gaaattgact  cgctcattgg  caaaggctcc  tttggccagg  tggtgaaagc  ctatgatcat
1081  cagaccagg  agcttgtggc  catcaagatc  atcaagaaca  aaaaggcttt  cctgaaccag
1141  gccagattg  agctgctggc  gctggagctg  atgaaccagc  atgacacgga  gatgaagtac
1201  tatatagtac  acctgaagcg  gcacttcatg  ttccggaacc  acctgtgcct  ggtatttgag
1261  ctgctgtcct  acaacctgta  cgacctcctg  cgcaacaccc  acttccgcgg  cgtctcgtg
1321  aacctgacct  ggaagctggc  gcagcagctc  tgacaggcac  tgctctttct  ggccacgcct
1381  gagctcagca  tcattcactg  cgacctcaag  cccgaaaaca  tcttgctgtg  caacccaag
1441  cgcagcgcca  tcaagattgt  ggacttcggc  agctcctgcc  agcttggcca  gaggatctac
  
```

Certificate of Analysis

```
1501 cagtatatcc agagccgctt ctaccgctca cctgaggtgc tcctgggcac accctacgac
1561 ctggccattg acatgtggtc cctgggctgc atccttgtgg agatgcacac cggagagccc
1621 ctcttcagtg gctccaatga ggtcgaccag atgaaccgca ttgtggaggt gctgggcatc
1681 ccaccggccg ccatgctgga ccaggcgcgc aaggctcgca agtacttga acggctgcct
1741 gggggtggct ggaccctacg aaggacgaaa gaactcagga aggattacca gggccccggg
1801 acacggcggc tgcaggaggt gctgggctg cagacgggcg ggccccgggg ccggcgggcg
1861 ggggagccgg gccacagccc cgccgactac ctccgcttc aggacctgt gctgcgcatg
1921 ctggagtatg agcccgccgc ccgcatcagc cccctggggg ctctgcagca cggcttcttc
1981 cgccgcacgg ccgacgaggc caccaacacg ggcccggcag gcagcagtgc ctccacctc
2041 cccgcgcccc tcgacacctg cccctcttc agcaccgcca gctccatctc cagttctgga
2101 ggctccagtg gtcctccag tgacaaccgg acctaccgct acagcaaccg atattgtggg
2161 ggccctgggc cccctatcac agactgtgag atgaacagc cccaggtccc accctcccag
2221 ccgctgcggc cctgggcagg gggatgatgt ccccacaaga cacatcaagc ccctgcctct
2281 gcctcgtcac tgcctgggac cggggcccag ttaccccc agccccgata ccttggctct
2341 cccccatcac caacctcacc accaccccc gagctgatgg atgtgagcct ggtgggcggc
2401 cctgctgact gctccccacc tcaccagcg cctgcccc agcaccggc tgcctcagcc
2461 ctccggactc ggatgactgg aggtcgtcca cccctcccgc ctctgatga ccctgccact
2521 ctggggcctc acctgggcct ccgtggtgta cccagagca cagcagccag ctcgtga
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services